



## Adult CIRB - Late Phase Emphasis Meeting Agenda

June 4, 2026

---

### I New Study - Initial Review

**A062401**, Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients with Primary Plasma Cell Leukemia: The QUANTUM Trial (Version Date 04/13/26)

---

### II New Study - Initial Review

**EAA232**, A Randomized Phase II Trial for High-Risk Multiple Myeloma that is Refractory or in First Relapse with Daratumumab, Teclistamab (DT) versus Daratumumab, Pomalidomide, dexamethasone (DPd) or Daratumumab, Carfilzomib, dexamethasone (DKd) (Version Date 05/13/26)

---

### III New Study - Initial Review

**S2506**, MOZART MZL: A Randomized Phase II Study Evaluating Mosunetuzumab Alone and in Combination with Either Zanubrutinib or Polatuzumab Vedotin for the Treatment of Participants with Relapsed/Refractory Marginal Zone Lymphoma (Version Date 04/17/26)

---

### IV Continuing Review

**A021901**, Randomized Phase II Trial of Lutetium Lu 177 Dotatate versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors (Version Date 02/05/25)

---

### V Continuing Review

**AMC-108**, Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma (Version Date 10/22/24)

## **VI Continuing Review**

**EA8231**, A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitean-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer (Version Date 04/03/26)

---

## **VII Continuing Review**

**NRG-BN013**, Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) versus Fractionated SRS (FSRS) for Intact Brain Metastases (Version Date 03/23/26)

---

## **VIII Continuing Review**

**NRG-BR009**, A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score  $\leq 25$  (OFSET) (Version Date 07/27/23)

---

## **IX Continuing Review**

**NRG-GY036**, A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy (Version Date 03/26/26)

---

## **X Continuing Review**

**S2206**, Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer (Version Date 03/26/25)

---



## **XI Continuing Review**

**SN2426**, A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma (Version Date 09/26/25)

---

## **XII Continuing Review**

**MYELOMATCH**, Master Screening and Reassessment Protocol for Tier Advancement in the NCI MyeloMATCH Clinical Trials (Version Date 07/14/25)

---